Limits...
Arginase-2 mediates diabetic renal injury.

Morris SM, Gao T, Cooper TK, Kepka-Lenhart D, Awad AS - Diabetes (2011)

Bottom Line: In contrast, arginase-1 expression was undetectable in kidneys under normal or diabetes conditions.The increase in kidney arginase activity was associated with a reduction in renal medullary blood flow in wild-type mice after 6 weeks of STZ-induced diabetes, an effect significantly attenuated in diabetic Arg2(-/-) mice.These findings indicate that arginase-2 plays a major role in induction of diabetic renal injury and that blocking arginase-2 activity or expression could be a novel therapeutic approach for treatment of DN.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ABSTRACT

Objective: To determine 1) whether renal arginase activity or expression is increased in diabetes and 2) whether arginase plays a role in development of diabetic nephropathy (DN).

Research design and methods: The impact of arginase activity and expression on renal damage was evaluated in spontaneously diabetic Ins2(Akita) mice and in streptozotocin (STZ)-induced diabetic Dilute Brown Agouti (DBA) and arginase-2-deficient mice (Arg2(-/-)).

Results: Pharmacological blockade or genetic deficiency of arginase-2 conferred kidney protection in Ins2(Akita) mice or STZ-induced diabetic renal injury. Blocking arginases using S-(2-boronoethyl)-L-cysteine for 9 weeks in Ins2(Akita) mice or 6 weeks in STZ-induced diabetic DBA mice significantly attenuated albuminuria, the increase in blood urea nitrogen, histopathological changes, and kidney macrophage recruitment compared with vehicle-treated Ins2(Akita) mice. Furthermore, kidney arginase-2 expression increased in Ins2(Akita) mice compared with control. In contrast, arginase-1 expression was undetectable in kidneys under normal or diabetes conditions. Arg2(-/-) mice mimicked arginase blockade by reducing albuminuria after 6 and 18 weeks of STZ-induced diabetes. In wild-type mice, kidney arginase activity increased significantly after 6 and 18 weeks of STZ-induced diabetes but remained very low in STZ-diabetic Arg2(-/-) mice. The increase in kidney arginase activity was associated with a reduction in renal medullary blood flow in wild-type mice after 6 weeks of STZ-induced diabetes, an effect significantly attenuated in diabetic Arg2(-/-) mice.

Conclusions: These findings indicate that arginase-2 plays a major role in induction of diabetic renal injury and that blocking arginase-2 activity or expression could be a novel therapeutic approach for treatment of DN.

Show MeSH

Related in: MedlinePlus

Arginase inhibition reduces increases in UAE in diabetic Ins2Akita mice. Ins2Akita and wild-type littermate mice were treated with BEC or vehicle via osmotic minipump for 9 weeks. Urine was collected for measurement of UAE before treatment (5 weeks of age) and after treatment (14 weeks of age). Open bar, vehicle-treated groups; filled bar, BEC-treated groups. Results are means ± SEM for n = 6–8 mice in each group.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3198072&req=5

Figure 1: Arginase inhibition reduces increases in UAE in diabetic Ins2Akita mice. Ins2Akita and wild-type littermate mice were treated with BEC or vehicle via osmotic minipump for 9 weeks. Urine was collected for measurement of UAE before treatment (5 weeks of age) and after treatment (14 weeks of age). Open bar, vehicle-treated groups; filled bar, BEC-treated groups. Results are means ± SEM for n = 6–8 mice in each group.

Mentions: To determine whether arginases contribute to diabetic renal injury, we measured 24-h UAE and BUN as indicators of renal injury in Ins2Akita with and without BEC treatment. Vehicle-treated Ins2Akita mice had a significant increase in albuminuria compared with controls at 5 and 14 weeks of age (Fig. 1). Albuminuria was significantly reduced in Ins2Akita mice treated with BEC at 14 weeks of age. Similarly, BUN was significantly increased in vehicle-treated Ins2Akita mice compared with other groups (Table 1).


Arginase-2 mediates diabetic renal injury.

Morris SM, Gao T, Cooper TK, Kepka-Lenhart D, Awad AS - Diabetes (2011)

Arginase inhibition reduces increases in UAE in diabetic Ins2Akita mice. Ins2Akita and wild-type littermate mice were treated with BEC or vehicle via osmotic minipump for 9 weeks. Urine was collected for measurement of UAE before treatment (5 weeks of age) and after treatment (14 weeks of age). Open bar, vehicle-treated groups; filled bar, BEC-treated groups. Results are means ± SEM for n = 6–8 mice in each group.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3198072&req=5

Figure 1: Arginase inhibition reduces increases in UAE in diabetic Ins2Akita mice. Ins2Akita and wild-type littermate mice were treated with BEC or vehicle via osmotic minipump for 9 weeks. Urine was collected for measurement of UAE before treatment (5 weeks of age) and after treatment (14 weeks of age). Open bar, vehicle-treated groups; filled bar, BEC-treated groups. Results are means ± SEM for n = 6–8 mice in each group.
Mentions: To determine whether arginases contribute to diabetic renal injury, we measured 24-h UAE and BUN as indicators of renal injury in Ins2Akita with and without BEC treatment. Vehicle-treated Ins2Akita mice had a significant increase in albuminuria compared with controls at 5 and 14 weeks of age (Fig. 1). Albuminuria was significantly reduced in Ins2Akita mice treated with BEC at 14 weeks of age. Similarly, BUN was significantly increased in vehicle-treated Ins2Akita mice compared with other groups (Table 1).

Bottom Line: In contrast, arginase-1 expression was undetectable in kidneys under normal or diabetes conditions.The increase in kidney arginase activity was associated with a reduction in renal medullary blood flow in wild-type mice after 6 weeks of STZ-induced diabetes, an effect significantly attenuated in diabetic Arg2(-/-) mice.These findings indicate that arginase-2 plays a major role in induction of diabetic renal injury and that blocking arginase-2 activity or expression could be a novel therapeutic approach for treatment of DN.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ABSTRACT

Objective: To determine 1) whether renal arginase activity or expression is increased in diabetes and 2) whether arginase plays a role in development of diabetic nephropathy (DN).

Research design and methods: The impact of arginase activity and expression on renal damage was evaluated in spontaneously diabetic Ins2(Akita) mice and in streptozotocin (STZ)-induced diabetic Dilute Brown Agouti (DBA) and arginase-2-deficient mice (Arg2(-/-)).

Results: Pharmacological blockade or genetic deficiency of arginase-2 conferred kidney protection in Ins2(Akita) mice or STZ-induced diabetic renal injury. Blocking arginases using S-(2-boronoethyl)-L-cysteine for 9 weeks in Ins2(Akita) mice or 6 weeks in STZ-induced diabetic DBA mice significantly attenuated albuminuria, the increase in blood urea nitrogen, histopathological changes, and kidney macrophage recruitment compared with vehicle-treated Ins2(Akita) mice. Furthermore, kidney arginase-2 expression increased in Ins2(Akita) mice compared with control. In contrast, arginase-1 expression was undetectable in kidneys under normal or diabetes conditions. Arg2(-/-) mice mimicked arginase blockade by reducing albuminuria after 6 and 18 weeks of STZ-induced diabetes. In wild-type mice, kidney arginase activity increased significantly after 6 and 18 weeks of STZ-induced diabetes but remained very low in STZ-diabetic Arg2(-/-) mice. The increase in kidney arginase activity was associated with a reduction in renal medullary blood flow in wild-type mice after 6 weeks of STZ-induced diabetes, an effect significantly attenuated in diabetic Arg2(-/-) mice.

Conclusions: These findings indicate that arginase-2 plays a major role in induction of diabetic renal injury and that blocking arginase-2 activity or expression could be a novel therapeutic approach for treatment of DN.

Show MeSH
Related in: MedlinePlus